Advanced Accelerator Applications (AAA) is an innovative radiopharmaceutical company that develops, produces and commercializes molecular nuclear medicine, or MNM, products.
AAA is a European leader in the production and commercialization of molecular nuclear diagnostic radiopharmaceuticals for PET and SPECT. These radiopharmaceuticals are mainly used for diagnosis in clinical oncology, cardiology and neurology.
AAA’s lead investigational therapeutic candidate, lutetium Lu 177 dotatate (Lutathera®) is a Lutetium-177, or Lu-177, labeled somatostatin analogue peptide in development for the treatment of neuroendocrine tumors, or NETs, a significant unmet medical need. A New Drug Application and Marketing Authorization Application for lutetium Lu 177 dotatate are currently under review with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Lutetium Lu 177 dotatate has received orphan drug designation from both the FDA and EMA.
AAA currently has 21 production and research & development facilities that manufacture both diagnostic and therapeutic Molecular Nuclear Medicine products, and over 530 employees in 13 countries (Belgium, Canada, France, Germany, Israel, Italy, the Netherlands, Poland, Portugal, Spain, Switzerland, UK and US).